TriLink BioTechnologies (TriLink) and the International Vaccine Institute (IVI), a non-profit international organization devoted to the discovery, development, and delivery of vaccines for global health, signed a Memorandum of Understanding (MOU). 

Together, the companies will collaborate to advance the research and development of mRNA-based vaccines and promote equitable access to essential vaccines and health technologies.

According to the terms of the MOU, TriLink and IVI will enter discussions on collaborative models to develop vaccines using mRNA technologies, facilitate knowledge exchange, and support joint scientific initiatives.

Since its launch in 2017, TriLink’s CleanCap capping technology has continued to advance the mRNA capping industry and is used in most of the approved COVID-19 mRNA and saRNA vaccines. 

In 2024, TriLink expanded its products and services specifically for customers working in mRNA therapeutics, launching IVT enzymes, including CleanScribe RNA polymerase, which has been shown to reduce dsRNA, and opened its commercially ready GMP manufacturing facility in San Diego, California.

IVI, based in Seoul, Korea, is an autonomous international organization established in 1997 as an initiative of the United Nations Development Program. 

It is dedicated to vaccines for global health, with a portfolio spanning all stages of pre-clinical and clinical development. Its work focuses on infectious diseases of global health importance, particularly those that disproportionately affect LMICs, including cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, and COVID-19.

“This collaboration will not only advance the science of mRNA-based vaccines but may also significantly enhance access to life-saving vaccines in low- and middle-income countries (LMICs),” said Maravai and TriLink’s Chief Commercial Officer, Becky Buzzeo. “By combining our expertise in nucleic acids with the International Vaccine Institute’s global reach and commitment to public health, we are poised to profoundly impact global health equity.”